NEOS Investment Management LLC Acquires 11,065 Shares of Eli Lilly and Company $LLY

Key Points

• NEOS Investment Management increased its Eli Lilly stake by 9.4% in the second quarter, adding 11,065 shares for a total holding of 128,460 shares valued at approximately $154.1 million. Institutional investors own 82.53% of the company.
• Eli Lilly executives sold 13,500 shares worth about $16.0 million over the past three months through pre-arranged Rule 10b5-1 plans, while insiders collectively own just 0.14% of the stock.
• The company reported strong quarterly results, with EPS of $8.38 and revenue of $22.97 billion, up 47.7% year over year. Analysts maintain a “Moderate Buy” consensus, and Lilly is expanding beyond obesity drugs through acquisitions such as its potential $2.88 billion purchase of Merida Biosciences.

NEOS Investment Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,460 shares of the company's stock after purchasing an additional 11,065 shares during the period. NEOS Investment Management LLC's holdings in Eli Lilly and Company were worth $154,079,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Burford Brothers Inc. acquired a new position in Eli Lilly and Company in the second quarter valued at approximately $1,068,000. Mason & Associates Inc grew its position in shares of Eli Lilly and Company by 2.1% during the 2nd quarter. Mason & Associates Inc now owns 963 shares of the company's stock worth $1,155,000 after buying an additional 20 shares during the period. Integrity Financial Corp WA increased its stake in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock valued at $767,000 after acquiring an additional 8 shares in the last quarter. Montz Harcus Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $268,000. Finally, KFG Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 171.3% during the 2nd quarter. KFG Wealth Management LLC now owns 1,378 shares of the company's stock valued at $1,653,000 after acquiring an additional 870 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Merida Biosciences for up to $2.88 billion, its 13th deal of the year. The transaction adds an early-stage immunology platform designed to selectively eliminate disease-causing autoantibodies while preserving normal immune function. Investors may view the acquisition as a way to diversify beyond Mounjaro and Zepbound and build longer-term growth in autoimmune and allergic diseases. Lilly looks beyond obesity with $2.88B autoimmune buyout
• Positive Sentiment: Lilly’s deal activity has outpaced other major pharmaceutical companies this year, reinforcing management’s efforts to replenish and broaden its pipeline. The strategy could reduce reliance on the obesity market over time, although many acquired programs remain early stage. This week in charts: China deals, stock flatlines and Lilly’s M&A spree
• Positive Sentiment: A Lilly subsidiary reached a late-stage development milestone involving an orexin receptor 2 agonist portfolio, triggering an $8.6 million payment to partner Nxera Pharma. The milestone provides evidence of pipeline progress, though the financial impact is modest relative to Lilly’s scale. Nxera Pharma milestone payment
• Neutral Sentiment: Local officials approved the final land-development plan for Lilly’s pharmaceutical plant in Upper Macungie, Pennsylvania. The step supports future manufacturing capacity and jobs but is unlikely to materially affect near-term earnings. Upper Macungie approves Lilly development plan
• Negative Sentiment: LLY is down about 2.7% since its latest earnings report, suggesting investors have been taking profits or looking for additional catalysts after the results. The quarter itself was strong—earnings and revenue exceeded expectations and revenue grew 47.7% year over year—but the stock’s premium valuation leaves limited room for disappointment. Lilly down since last earnings report
• Negative Sentiment: Superluminal Medicines raised $60 million to advance an early-stage MC4R obesity treatment. Although years from commercialization, additional funding for competing obesity therapies highlights the potential for greater competition around Lilly’s core growth market. Superluminal advances rare obesity therapy

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Citigroup increased their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 15th. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an "overweight" rating in a report on Tuesday, July 7th. Sanford C. Bernstein increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 14th. Finally, The Goldman Sachs Group restated a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Down 0.2%

Eli Lilly and Company stock opened at $1,147.06 on Monday. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The stock has a market cap of $1.08 trillion, a PE ratio of 38.49, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The firm's 50-day simple moving average is $1,191.71 and its 200 day simple moving average is $1,069.87. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the business posted $6.31 EPS. The company's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts predict that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source